Join

Compare · NVO vs ZYME

NVO vs ZYME

Side-by-side comparison of Novo Nordisk A/S (NVO) and Zymeworks Inc. (ZYME): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and ZYME operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $173.66B, about 441.5x ZYME ($393.4M).
  • Over the past year, NVO is down 30.4% and ZYME is up 36.8% - ZYME leads by 67.1 points.
  • ZYME has been more active in the news (5 items in the past 4 weeks vs 3 for NVO).
  • Both have 25 recent analyst ratings on file.
PerformanceNVO-30.36%ZYME+36.78%
2025-10-20+0.00%2026-10-16
MetricNVOZYME
Company
Novo Nordisk A/S
Zymeworks Inc.
Price
$38.82-1.05%
$25.03-2.95%
Market cap
$173.66B
$393.4M
1M return
-10.14%
-9.01%
1Y return
-30.36%
+36.78%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NYSE
IPO
News (4w)
3
5
Recent ratings
25
25
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

ZYME

Zymeworks Inc.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Latest NVO

Latest ZYME